双特异性抗体在多发性骨髓瘤免疫治疗中的研究进展
Advances in the Research of Bispecific Antibodies in Immunotherapy for Multiple Myeloma
DOI: 10.12677/jcpm.2026.53213, PDF,   
作者: 利 浩, 王聪颖, 温才宁*：济宁医学院临床医学院，山东 济宁
关键词: 多发性骨髓瘤；免疫治疗；双特异性抗体；Multiple Myeloma； Immunotherapy； Bispecific Antibody
摘要: 多发性骨髓瘤是血液系统高发的恶性肿瘤，治疗后容易耐药及复发。近年来，免疫治疗尤其是双特异性抗体的应用，为该疾病治疗带来了突破性进展，显著改变了复发/难治性多发性骨髓瘤的治疗格局。本文系统综述双特异性抗体的作用机制、临床研究进展及当前面临的挑战，并展望其未来发展方向，以推动多发性骨髓瘤精准免疫治疗的进一步发展。
Abstract: Multiple myeloma is a highly prevalent malignant tumor in the hematological system. After treatment, it is prone to develop drug resistance and recurrence. In recent years, the application of immunotherapy, especially bispecific antibodies, has brought breakthrough progress in the treatment of this disease, significantly altering the treatment landscape for relapsed/refractory multiple myeloma. This article systematically reviews the mechanism of action, clinical research progress and current challenges of bispecific antibodies, and looks forward to their future development directions, in order to promote the further advancement of precise immunotherapy for multiple myeloma.
文章引用：利浩, 王聪颖, 温才宁. 双特异性抗体在多发性骨髓瘤免疫治疗中的研究进展[J]. 临床个性化医学, 2026, 5(3): 324-333. https://doi.org/10.12677/jcpm.2026.53213

参考文献

[1] Kumar, S.K., Rajkumar, V., Kyle, R.A., van Duin, M., Sonneveld, P., Mateos, M., et al. (2017) Multiple Myeloma. Nature Reviews Disease Primers, 3, Article No. 17046. [Google Scholar] [CrossRef] [PubMed]
[2] 赵艺涵, 孙旭杭, 赵琳, 等. 外泌体miRNA治疗多发性骨髓瘤的作用与机制[J]. 中国组织工程研究, 2025, 29(31): 6743-6752.
[3] Cowan, A.J., Green, D.J., Kwok, M., Lee, S., Coffey, D.G., Holmberg, L.A., et al. (2022) Diagnosis and Management of Multiple Myeloma: A Review. JAMA, 327, 464-477. [Google Scholar] [CrossRef] [PubMed]
[4] 王珺, 刘爱春. 多发性骨髓瘤的免疫治疗研究进展[J]. 现代肿瘤医学, 2022, 30(12): 2263-2267.
[5] Sorgiovanni, I., Del Giudice, M.L., Galimberti, S. and Buda, G. (2025) Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma. Pharmaceuticals, 18, Article 145. [Google Scholar] [CrossRef] [PubMed]
[6] Klein, C., Brinkmann, U., Reichert, J.M. and Kontermann, R.E. (2024) The Present and Future of Bispecific Antibodies for Cancer Therapy. Nature Reviews Drug Discovery, 23, 301-319. [Google Scholar] [CrossRef] [PubMed]
[7] Ludwig, H., Terpos, E., van de Donk, N., Mateos, M., Moreau, P., Dimopoulos, M., et al. (2023) Prevention and Management of Adverse Events during Treatment with Bispecific Antibodies and CAR T Cells in Multiple Myeloma: A Consensus Report of the European Myeloma Network. The Lancet Oncology, 24, e255-e269. [Google Scholar] [CrossRef] [PubMed]
[8] Pao, S.-C., Chu, M.-T. and Hung, S.-I. (2022) Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers. Pharmaceutics, 14, Article 867. [Google Scholar] [CrossRef] [PubMed]
[9] Zhou, Y., Penny, H.L., Kroenke, M.A., Bautista, B., Hainline, K., Chea, L.S., et al. (2022) Immunogenicity Assessment of Bispecific Antibody-Based Immunotherapy in Oncology. Journal for ImmunoTherapy of Cancer, 10, e004225. [Google Scholar] [CrossRef] [PubMed]
[10] 肖婉婷, 张春燕, 田彪, 等. 复发/难治性多发性骨髓瘤免疫治疗新策略: GPRC5D双特异性抗体[J]. 中国癌症防治杂志, 2024, 16(4): 399-404.
[11] 李永超, 杨昭. 双特异抗体药物研发现状及发展对策[J]. 生物技术进展, 2023, 13(3): 353-358.
[12] Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A.K., Schuh, A.C., Ribera, J., et al. (2017) Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. New England Journal of Medicine, 376, 836-847. [Google Scholar] [CrossRef] [PubMed]
[13] Zhou, C., Tang, K., Cho, B.C., Liu, B., Paz-Ares, L., Cheng, S., et al. (2023) Amivantamab Plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. New England Journal of Medicine, 389, 2039-2051. [Google Scholar] [CrossRef] [PubMed]
[14] Frerichs, K.A., Broekmans, M.E.C., Marin Soto, J.A., van Kessel, B., Heymans, M.W., Holthof, L.C., et al. (2020) Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab. Clinical Cancer Research, 26, 2203-2215. [Google Scholar] [CrossRef] [PubMed]
[15] Touzeau, C., Krishnan, A.Y., Moreau, P., Perrot, A., Usmani, S.Z., Manier, S., et al. (2024) Efficacy and Safety of Teclistamab in Patients with Relapsed/refractory Multiple Myeloma after BCMA-Targeting Therapies. Blood, 144, 2375-2388. [Google Scholar] [CrossRef] [PubMed]
[16] Firestone, R., Lesokhin, A.M. and Usmani, S.Z. (2023) An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma. Blood Cancer Discovery, 4, 433-436. [Google Scholar] [CrossRef] [PubMed]
[17] Moreau, P., Garfall, A.L., van de Donk, N.W.C.J., Nahi, H., San-Miguel, J.F., Oriol, A., et al. (2022) Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 387, 495-505. [Google Scholar] [CrossRef] [PubMed]
[18] Costa, L.J., Bahlis, N.J., Perrot, A., Nooka, A.K., Lu, J., Pawlyn, C., et al. (2026) Teclistamab Plus Daratumumab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 394, 739-752. [Google Scholar] [CrossRef] 
[19] 韩帆, 张雪鹏, 席亚明. 双特异性抗体在多发性骨髓瘤治疗中的研究进展[J]. 中国实验血液学杂志, 2024, 32(3): 952-956.
[20] Lesokhin, A.M., Tomasson, M.H., Arnulf, B., Bahlis, N.J., Miles Prince, H., Niesvizky, R., et al. (2023) Elranatamab in Relapsed or Refractory Multiple Myeloma: Phase 2 Magnetismm-3 Trial Results. Nature Medicine, 29, 2259-2267. [Google Scholar] [CrossRef] [PubMed]
[21] Bumma, N., Richter, J., Jagannath, S., Lee, H.C., Hoffman, J.E., Suvannasankha, A., et al. (2024) Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology, 42, 2702-2712. [Google Scholar] [CrossRef] [PubMed]
[22] D’Souza, A., Shah, N., Rodriguez, C., Voorhees, P.M., Weisel, K., Bueno, O.F., et al. (2022) A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology, 40, 3576-3586. [Google Scholar] [CrossRef] [PubMed]
[23] Waldschmidt, J.M., Rasche, L., Kortüm, K.M. and Einsele, H. (2025) Comprehensive Review of Bispecific Antibody Constructs in Multiple Myeloma: Affinities, Dosing Strategies and Future Perspectives. Clinical Lymphoma Myeloma and Leukemia, 25, 309-315. [Google Scholar] [CrossRef] [PubMed]
[24] Fei, K., Ni, H., Zhu, M., Kuang, Z., Wu, M., Wu, Z., et al. (2022) IBI379, a Novel B Cell Maturation Antigen/CD3 Bispecific T-Cell Engager, Displays High Antitumor Efficacy in Preclinical Models of Multiple Myeloma. Cancer Letters, 536, 215663. [Google Scholar] [CrossRef] [PubMed]
[25] Verkleij, C.P.M., Frerichs, K.A., Broekmans, M., Absalah, S., Maas-Bosman, P.W.C., Kruyswijk, S., et al. (2020) T-cell Redirecting Bispecific Antibodies Targeting BCMA for the Treatment of Multiple Myeloma. Oncotarget, 11, 4076-4081. [Google Scholar] [CrossRef] [PubMed]
[26] Topp, M.S., Duell, J., Zugmaier, G., Attal, M., Moreau, P., Langer, C., et al. (2020) Anti-b-Cell Maturation Antigen Bite Molecule AMG 420 Induces Responses in Multiple Myeloma. Journal of Clinical Oncology, 38, 775-783. [Google Scholar] [CrossRef] [PubMed]
[27] Kiesel, B., Osawa, M., Masilamani, M., Bar, M., Hsu, K., Godwin, C., et al. (2024) Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T-Cell Engager, Using Population Pharmacokinetics and Exposure-Response Analysis. Clinical Pharmacology & Therapeutics, 116, 866-874. [Google Scholar] [CrossRef] [PubMed]
[28] Mailankody, S., Devlin, S.M., Landa, J., Nath, K., Diamonte, C., Carstens, E.J., et al. (2022) GPRC5D-Targeted CAR T Cells for Myeloma. New England Journal of Medicine, 387, 1196-1206. [Google Scholar] [CrossRef] [PubMed]
[29] Zhou, D., Wang, Y., Chen, C., Li, Z., Xu, K. and Zhao, K. (2024) Targeting GPRC5D for Multiple Myeloma Therapy. Journal of Hematology & Oncology, 17, Article No. 88. [Google Scholar] [CrossRef] [PubMed]
[30] Chari, A., Minnema, M.C., Berdeja, J.G., Oriol, A., van de Donk, N.W.C.J., Rodríguez-Otero, P., et al. (2022) Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. New England Journal of Medicine, 387, 2232-2244. [Google Scholar] [CrossRef] [PubMed]
[31] Eckmann, J., Fauti, T., Biehl, M., Zabaleta, A., Blanco, L., Lelios, I., et al. (2025) Forimtamig, a Novel GPRC5D-Targeting T-Cell Bispecific Antibody with a 2 + 1 Format, for the Treatment of Multiple Myeloma. Blood, 145, 202-219. [Google Scholar] [CrossRef] [PubMed]
[32] 安嘉颖, 潘萌萌, 欧阳皖雁, 等. 靶向GPRC5D治疗多发性骨髓瘤的研究进展[J]. 中华血液学杂志, 2024, 45(9): 883-888.
[33] Tomita, U., Ishimoto, Y., Ri, M., Kawase, Y., Hizukuri, Y., Maru, C., et al. (2024) A Novel T Cell-Redirecting Anti-GPRC5D × CD3 Bispecific Antibody with Potent Antitumor Activity in Multiple Myeloma Preclinical Models. Scientific Reports, 14, Article No. 5135. [Google Scholar] [CrossRef] [PubMed]
[34] Ise, T., Nagata, S., Kreitman, R.J., Wilson, W.H., Wayne, A.S., Stetler-Stevenson, M., et al. (2007) Elevation of Soluble CD307 (IRTA2/FcRH5) Protein in the Blood and Expression on Malignant Cells of Patients with Multiple Myeloma, Chronic Lymphocytic Leukemia, and Mantle Cell Lymphoma. Leukemia, 21, 169-174. [Google Scholar] [CrossRef] [PubMed]
[35] Zhao, J., Ren, Q., Liu, X., Guo, X. and Song, Y. (2023) Bispecific Antibodies Targeting BCMA, GPRC5D, and FCRH5 for Multiple Myeloma Therapy: Latest Updates from ASCO 2023 Annual Meeting. Journal of Hematology & Oncology, 16, Article No. 92. [Google Scholar] [CrossRef] [PubMed]
[36] Ravi, G. and Costa, L.J. (2022) Bispecific T‐Cell Engagers for Treatment of Multiple Myeloma. American Journal of Hematology, 98, S13-S21. [Google Scholar] [CrossRef] [PubMed]
[37] Pahl, J.H.W., Koch, J., Götz, J., Arnold, A., Reusch, U., Gantke, T., et al. (2018) CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells. Cancer Immunology Research, 6, 517-527. [Google Scholar] [CrossRef] [PubMed]
[38] Kakiuchi-Kiyota, S., Ross, T., Wallweber, H.A., Kiefer, J.R., Schutten, M.M., Adedeji, A.O., et al. (2022) A BCMA/CD16A Bispecific Innate Cell Engager for the Treatment of Multiple Myeloma. Leukemia, 36, 1006-1014. [Google Scholar] [CrossRef] [PubMed]
[39] Plesner, T., Harrison, S.J., Quach, H., Lee, C., Bryant, A., Vangsted, A., et al. (2023) Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16A Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma. Clinical Hematology International, 5, 43-51. [Google Scholar] [CrossRef] [PubMed]
[40] Shao, Y., Zhang, Y., Cao, J., He, J., He, Q., Lei, Y., et al. (2025) NKp30: A Key Membrane Molecule in the Fight against Cancer and Infection. The FASEB Journal, 39, e70856. [Google Scholar] [CrossRef] [PubMed]
[41] Tedder, B. and Bhutani, M. (2025) Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma. Cells, 14, Article 1077. [Google Scholar] [CrossRef] [PubMed]
[42] Lee, H., Durante, M., Skerget, S., Vishwamitra, D., Benaoudia, S., Ahn, S., et al. (2024) Impact of Soluble BCMA and Non-t-Cell Factors on Refractoriness to BCMA-Targeting T-Cell Engagers in Multiple Myeloma. Blood, 144, 2637-2651. [Google Scholar] [CrossRef] [PubMed]
[43] Pont, M.J., Hill, T., Cole, G.O., Abbott, J.J., Kelliher, J., Salter, A.I., et al. (2019) Γ-Secretase Inhibition Increases Efficacy of BCMA-Specific Chimeric Antigen Receptor T Cells in Multiple Myeloma. Blood, 134, 1585-1597. [Google Scholar] [CrossRef] [PubMed]
[44] Kim, J., Park, S., Kim, J., Kim, Y., Yoon, H.M., Rayhan, B.R., et al. (2025) Trogocytosis-Mediated Immune Evasion in the Tumor Microenvironment. Experimental & Molecular Medicine, 57, 1-12. [Google Scholar] [CrossRef] [PubMed]
[45] 刘夏鑫, 徐子真, 李军民. T细胞耗竭在血液系统肿瘤中的最新研究进展[J]. 中国实验血液学杂志, 2025, 33(2): 606-611.
[46] van de Donk, N.W.C.J., Moreau, P., San‐Miguel, J.F., Mateos, M., Dimopoulos, M.A., Zweegman, S., et al. (2025) Sequencing BCMA‐ and Gprc5d‐Targeting Immunotherapies in Multiple Myeloma: Practical Guidance from the European Myeloma Network. HemaSphere, 9, e70260. [Google Scholar] [CrossRef] 
[47] Mohan, M., Van Oekelen, O., Akhtar, O.S., Cohen, A. and Parekh, S. (2024) Charting the Course: Sequencing Immunotherapy for Multiple Myeloma. American Society of Clinical Oncology Educational Book, 44, e432204. [Google Scholar] [CrossRef] [PubMed]